1. Impact of Chemotherapy Regimens on Body Composition of Breast Cancer Women: A Multicenter Study across Four Brazilian Regions.
- Author
-
Godinho-Mota JCM, Vaz-Gonçalves L, Dias Custódio ID, Schroeder de Souza J, Mota JF, Gonzalez MC, Rodrigues Vilella P, Anusca Martins K, Paiva Maia YC, Verde SMML, Frenzel AP, Di Pietro PF, Costa Marinho ED, and Freitas-Junior R
- Subjects
- Humans, Female, Brazil, Body Composition, Docetaxel therapeutic use, Cyclophosphamide therapeutic use, Fluorouracil therapeutic use, Body Mass Index, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms drug therapy
- Abstract
This study aimed to investigate the effect of chemotherapy (CT) and its different types of regimens on the anthropometry and body composition of women with breast cancer. Three-hundred-and-four women with breast cancer were enrolled in this multicenter study. The participants were evaluated before the infusion of the first cycle of CT (pre-CT), and until two weeks after CT completion (post-CT), regarding body weight, body mass index (BMI); waist circumference (WC); waist-to-height ratio (WHtR); conicity index (C-index); fat mass index (FMI); and fat-free mass index (FFMI). CT regimens were classified as anthracycline-based (AC-doxorubicin or epirubicin); anthracyclines and taxane (ACT); cyclophosphamide, methotrexate, and 5-fluorouracil (CMF); or isolated taxanes (paclitaxel or docetaxel). Women significantly increased BMI and FMI post-CT ( p < 0.001 and p = 0.007, respectively). The ACT regimen increased FMI ( p < 0.001), while FFMI increased after AC ( p = 0.007). It is concluded that the CT negatively impacted body composition and the type of regime had a strong influence. The ACT regimen promoted an increase in FMI compared to other regimens, and the AC increased FFMI. These findings reinforce the importance of nutritional monitoring of breast cancer patients throughout the entire CT treatment.
- Published
- 2023
- Full Text
- View/download PDF